Detalhe da pesquisa
1.
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
Diabetes Obes Metab
; 21(7): 1752-1756, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30924578
2.
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.
Diabetes Ther
; 10(1): 177-188, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30547388
3.
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Diabetes Care
; 40(7): 951-957, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28483786
4.
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Diabetes Care
; 38(3): 365-72, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25592197
5.
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957.
Diabetes Care
; 41(3): e29-e30, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463670
6.
Foot Care.
Can J Diabetes
; 42 Suppl 1: S222-S227, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29650101
7.
Foot care.
Can J Diabetes
; 37 Suppl 1: S145-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24070938